Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Agilent inaugurates India Solution Center to accelerate innovation and expand the frontiers of…
Integrated facility aims to deliver end-to-end, customised workflows across lifesciences, diagnostics, and applied markets
Accretion Pharmaceuticals’ IPO to open on May 14 2025; Price band fixed at ₹96-101
The company aims to utilise the funds towards purchasing new equipment, upgrading the manufacturing plant and repayment of certain…
HIV market to exceed $32 bn across 7MM in 2033, forecasts GlobalData
Market growth will primarily be driven by the increased uptake of long-acting injectable therapies, as well as the anticipated…
Coliform bacteria and E. coli in pharma water systems: A hidden threat to product integrity
Water quality is critical in pharma manufacturing, and contamination by coliforms or E. coli can threaten product safety and…
Pharma CRDMO revenue forecasts 13-15 per cent growth amid supply-chain derisking
Resultant strong cash flows will enable Indian CRDMOs to continue capital expenditure (capex), with limited reliance on debt…
Enterprise Risk Management (ERM): A critical imperative for India’s pharma sector
Gurmeet Singh, Procurement Director, Alfa Pharma, highlights how risk-resilient practices can strengthen the Indian pharma…
We are well-aligned to capitalise on the CDMO opportunity
Dr Abdelaziz Toumi, CEO, Lupin Manufacturing Solutions (LMS), explains to Viveka Roychowdhury how LMS is aligning long-term…
Lupin gains USFDA nod for Raltegravir Tablets USP, 600 mg
Being the exclusive first-to-file, Lupin is eligible for 180-day generic exclusivity
AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low…
The medicine is now indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic breast cancer
FABA, IIL, and ABF launch finishing school programme in Hyderabad
The month-long programme provides intensive, hands-on training in wet lab facilities, offering real-world experience in…